Rituximab, bendamustine and cytarabine (R-BAC) in patients with relapsed-refractory aggressive B-cell lymphoma

Am J Hematol. 2018 Dec;93(12):E386-E389. doi: 10.1002/ajh.25278. Epub 2018 Oct 9.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Multicenter Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / toxicity
  • Bendamustine Hydrochloride / therapeutic use
  • Cytarabine / therapeutic use
  • Female
  • Humans
  • Italy
  • Lymphoma, B-Cell / drug therapy*
  • Lymphoma, Large B-Cell, Diffuse / drug therapy*
  • Male
  • Middle Aged
  • Pilot Projects
  • Rituximab / therapeutic use
  • Salvage Therapy / methods*
  • Treatment Outcome
  • Young Adult

Substances

  • Cytarabine
  • Rituximab
  • Bendamustine Hydrochloride